

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

FINN et al.

Atty. Ref.: 620-379

Serial No. 10/542,281

Group: unknown

Filed: July 15, 2005

Examiner: Unknown

For: CARBAMIC ACID COMPOUNDS COMPRISING AN  
ESTER OR KETONE LINKAGE AS HDAC INHIBITORS

\* \* \* \* \*

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

August 11, 2005

Sir:

**INFORMATION DISCLOSURE STATEMENT**

- ☒ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**  
[within 3 months of filing or prior to 1st Office Action on the merits]  
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e)  
Statement or Rule 17(p) fee)]  
N/C
- ☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e)  
Statement or Rule 17(p) fee)]  
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**  
[after Final Office Action or Allowance (requires Rule 97(e)  
Statement and Rule 17(p) fee), but before final fee payment]  
\$180.00

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:

- ☒ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- ☐ a) The required Statement made in item 8 below; or
- ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
- ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,  
NIXON & VANDERHYE P.C.

By: \_\_\_\_\_



B. J. Sadoff

Reg. No. 36,663

901 North Glebe Road, 11th Floor  
Arlington, VA 22203-1808  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

**INFORMATION DISCLOSURE  
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

620-379

10/542,281

APPLICANT

FINN et al.

(Use several sheets if necessary)

FILING DATE

GROUP

July 15, 2005

unknown

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,834,249	11/1998	Furukawa et al.			

**FOREIGN PATENT DOCUMENTS**

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO
WO 99/02510 /	01/1999	WIPO				
WO 99/24399 /	05/1999	WIPO				
WO 00/12477 /	03/2000	WIPO				
WO 00/12478 /	03/2000	WIPO				
WO 00/37436 /	06/2000	WIPO				
WO 00/46221 /	08/ 2000	WIPO				
WO 00/56704 /	09/2000	WIPO				
WO 00/69819 /	11/2000	WIPO				
WO 00/69839 /	11/2000	WIPO				
WO 01/10834 /	02/2001	WIPO				
WO 01/38322 /	05/2001	WIPO				
WO 01/44189 /	06/2001	WIPO				
WO 01/62751 /	08/ 2001	WIPO				
WO 01/85680 /	11/2001	WIPO				
WO 01/87870 /	11/2001	WIPO				
WO 02/22577 /	03/2002	WIPO				
WO 02/26696 /	04/2002	WIPO				
WO 02/26703 /	04/2002	WIPO				
WO 02/28829 /	04/2002	WIPO				
WO 02/30879 /	04/2002	WIPO				
EP 0 574 758 /	12/1993	Europe				
EP 0 827 742 /	03/1998	Europe				
EP 0 684 240 /	11/1995	Europe				
JP 10-114681	05/1998	Japan				
JP 57-077646 /	05/1982	Japan				
JP 49-000243 /	01/1974	Japan				
JP 04-217950 /	08/1992	Japan				

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

	Andrews et al., 2000, "Anti-malarial effect of histone deacetylation inhibitors and mammalian tumour cytodifferentiating agents," <u>Int. J. Parasitol.</u> , Vol. 30, No. 6, pp. 761-768.
	Barta et al., 2000, "Synthesis and activity of selective MMP inhibitors with an aryl backbone," <u>Bioorg. Med. Chem. Lett.</u> , Vol. 10, No. 24, pp. 2815-2817.

*Examiner	Date Considered
-----------	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

**INFORMATION DISCLOSURE  
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

620-379

10/542,281

APPLICANT

FINN et al.

(Use several sheets if necessary)

FILING DATE

GROUP

July 15, 2005

unknown

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

	Bernhard, D. et al., 1999, "Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts," <u>FASEB J.</u> , Vol. 13, No. 14, pp. 1991-2001.
	Bernstein et al., 2000, "Genomewide studies of histone deacetylase function in yeast," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 97, No. 25, pp. 13708-13713.
	Brehm, A., et al., 1998, "Retinoblastoma protein recruits histone deacetylase to repress transcription," <u>Nature</u> , 1998, Vol. 391, pp. 597-601.
	Chang et al., 2000, "Activation of the BRLF1 promoter and lytic cycle of Epstein-Barr virus by histone acetylation," <u>Nucleic Acids Res.</u> , Vol. 28, No. 20, pp. 3918-3925.
	Dangond et al., 1998, Differential Display Cloning of a Novel Human Histone Deacetylase (HDAC3) cDNA from PHA-Activated Immune Cells," <u>Biochem. Biophys. Res. Commun.</u> , Vol. 242, No. 3, pp. 648-652.
	David, G., et al., 1998, "Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein," <u>Oncogene</u> , Vol. 16(19), pp. 2549-2556.
	Davie, J.R., 1998, "Covalent modifications of histones: expression from chromatic templates," <u>Curr. Opin. Genet. Dev.</u> , Vol. 8, pp. 173-178.
	Desai, D., et al., 1999, "Chemopreventive efficacy of suberanilohydroxamic acid (SAHA), a cytodifferentiating agent, against tobacco-specific nitrosamine 4-(methylnitros-amino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in female A/J mice," <u>Proceedings of the American Association for Cancer Research, Prevention/Basic Science and Clinical Studies 4</u> , Vol. 40, p. 362, Abstract No. 2396.
	Desmarests, C., et al., 2001, Nickel-catalysed sequential amination of aryl- and heteroaryl di- and trichlorides," <u>Tetrahedron</u> , Vol. 57, pp. 7657-7664.
	Emiliani, S., et al., 1998, "Characterization of a human RPD3 ortholog, HDAC3," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 95, p. 2795-2800.
	Finnin et al., 1999, "Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors," <u>Nature</u> , Vol. 401, pp. 188-193.
	Grotinger et al., 1999, "Three proteins define a class of human histone deacetylases related to yeast Hda1p," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 96, pp. 4868-4873.
	Hartwig, J.F., et al., 1999, "Room-Temperature Palladium-Catalyzed Amination of Aryl Bromides and Chlorides and Extended Scope of Aromatic C-N Bond Formation with a Commercial Ligand," <u>J. Org. Chem.</u> , Vol. 64, pp. 5575-5580.
	Hoshikawa, Y., et al., 1994, "Trichostatin A Induces Morphological Changes and Gelsolin Expression by Inhibiting Histone Deacetylase in Human Carcinoma Cell Lines," <u>Exp. Cell. Res.</u> , Vol. 214(1), pp. 189-197.

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

**INFORMATION DISCLOSURE  
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

620-379

10/542,281

APPLICANT

FINN et al.

(Use several sheets if necessary)

FILING DATE

GROUP

July 15, 2005

unknown

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

	Hou et al., 2001, "Binding affinities for a series of selective inhibitors of gelatinase-A using molecular dynamics with a linear interaction energy approach," <u>J. Phys. Chem. B</u> , Vol. 105, No. 22, pp. 5304-5315.
	Howe, L., et al., 1999, "Histone Acetyltransferase Complexes and Their Link to Transcription," <u>Crit. Rev. Eukaryot. Gene Expr.</u> , Vol. 9(3-4), pp. 231-243.
	Iavarone et al., 1999, "E2F and Histone Deacetylase Mediate Transforming Growth Factor $\beta$ Repression of <i>cdc25A</i> during Keratinocyte Cell Cycle Arrest," <u>Mol. Cell Biol.</u> , Vol. 19, No. 1, pp. 916-922.
	Jung, M., et al., 1999, " <u>Journal of Medicinal Chemistry</u> (ACS, Washington, USA), Vol. 42, No. 22, pp. 4669-4679.
	Kao et al., 2000, "Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression," <u>Genes &amp; Dev.</u> , Vol. 14, p. 55-66.
	Kijima et al., 1993, "Trapoxin, an Antitumor Cyclic Tetrapeptide, Is an Irreversible Inhibitor of Mammalian Histone Deacetylase*," <u>J. Biol. Chem.</u> , Vol. 268, pp. 22429-22435.
	Kim et al., 1999, "Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase," <u>Oncogene</u> , Vol. 18(15), pp. 2461-2470.
	Kim, M.S., et al., 2001 "Histone deacetylases induce angiogenesis by negative regulation of tumour suppressor genes," <u>Nature Medicine</u> , Vol 7, No. 4, pp. 437-443.
	Kimura et al., 1994, "Dual Modes of Action of Platelet-Derived Growth Factor and Its Inhibition by Trichostatin-A for DNA Synthesis in Primary Cultured Smooth Muscle Cells of Rat Aorta," <u>Biol. Pharm. Bull.</u> , Vol. 17, No. 3, pp. 399-402.
	Kitamura, K., et al., 2000, "Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid," <u>Br. J. Haematol.</u> , Vol. 108(4), pp. 696-702.
	Kompis, I, Wick, A., 1977, "Synthesis of 4-halo-substituted analogs of trimethoprim," <u>Helv. Chim. Acta.</u> , Vol. 60, No. 8, pp. 3025-3034.
	Kouzarides, T., 1999, "Histone acetylases and deacetylases in cell proliferation," <u>Curr. Opin. Genet. Dev.</u> , Vol. 9, No. 1, pp. 40-48.
	Kuusisto et al., 2001, "Ubiquitin-Binding Protein p62 Expression is Induced during Apoptosis and Proteasomal Inhibition in Neuronal Cells," <u>Biochem. Biophys. Res. Commun.</u> , Vol. 280, No. 1, pp. 223-228.
	Kwon et al., 1998, "Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 95, pp. 3356-3361.
	Laherty, C.D., et al., 1997, "Histone Deacetylases Associated with the mSin3 Corepressor Mediate Mad Transcriptional Repression," <u>Cell</u> , Vol. 89(3), pp. 349-356.

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

**INFORMATION DISCLOSURE  
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

620-379

10/542,281

APPLICANT

FINN et al.

(Use several sheets if necessary)

FILING DATE

GROUP

July 15, 2005

unknown

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

	Lea and Tulsyan, 1995, "Discordant Effects of Butyrate Analogues on Erythroleukemia Cell Proliferation, Differentiation and Histone Deacetylase," <u>Anticancer Res.</u> , Vol. 15, pp. 879-883.
	Lea et al., 1999, "Increased acetylation of histones induced by diallyl disulfide and structurally related molecules," <u>Int. J. Oncol.</u> , Vol. 2, pp. 347-352.
	Lin, R.J., et al., 1998, "Role of the histone deacetylase complex in acute promyelocytic leukaemia," <u>Nature</u> , Vol. 391(6669), pp. 811-814.
	McCaffrey et al., 1997, "Induction of $\gamma$ -Globin by Histone Deacetylase Inhibitors," <u>Blood</u> , Vol. 90, No. 5, pp. 2075-2083.
	Mielnicki, L.M., et al., 1999, "Epigenetic Regulation of Gelsolin Expression in Human Breast Cancer Cells," <u>Exp. Cell. Res.</u> , Vol. 249(1), pp. 161-176.
	Nakajima et al., 1998, "FR901228, a Potent Antitumor Antibiotic, Is a Novel Histone Deacetylase Inhibitor," <u>Exp. Cell Res.</u> , Vol. 241, pp. 126-133.
	Ng, H.H. and Bird, A., 2000, "Histone deacetylases: silencers for hire," <u>Trends Biochem. Sci.</u> , Vol. 25(3), pp. 121-126.
	Niki et al., 1999, "A Histone Deacetylase Inhibitor, Trichostatin A, Suppresses Myofibroblastic Differentiation of Rat Hepatic Stellate Cells in Primary Culture," <u>Hepatology</u> , Vol. 29, No. 3, pp. 858-867.
	Onishi et al., 1996, "Antibacterial Agents That Inhibit Lipid A Biosynthesis," <u>Science</u> , Vol. 274, pp. 980-982.
	Parrish, C.A., et al., 2001, "Use of Polymer-Supported Dialkylphosphinobiphenyl Ligands for Palladium-Catalyzed Amination and Suzuki Reactions," <u>J. Org. Chem.</u> , Vol. 66, pp. 3820-3827.
	Pazin, M.J., et al., 1997, "What's up and down with histone deacetylation and transcription?," <u>Cell</u> , Vol. 89, No. 3, pp. 325-328.
	Richon et al, 1996, "Second generation hybrid polar compounds are potent inducers of transformed cell differentiation," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 93, pp. 5705-5708.
	Richon et al., 1998, "A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 95, pp. 3003-3007.
	Saito et al., 1999, "A synthetic inhibitor of histone deacetylase, MS-27-275, with marked <i>in vivo</i> antitumor activity against human tumors," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 96, pp. 4592-4597.
	Saunders, N. et al, 1999 "Histone deacetylase inhibitors as potential anti-skin cancer agents," <u>Cancer Res.</u> , Vol. 59, No. 2 pp. 399-404.

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

**INFORMATION DISCLOSURE  
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

620-379

10/542,281

APPLICANT

FINN et al.

(Use several sheets if necessary)

FILING DATE

GROUP

July 15, 2005

unknown

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

	Sonoda, H. et al., 1996, "Oxamflatin: a novel compound which reverses malignant phenotype to normal one via induction of JunD," <u>Oncogene</u> , Vol. 13, pp. 143-149.
	Spencer, V.A. and Davie, J.R., 1999, "Role of covalent modifications of histones in regulating gene expression," <u>Gene</u> , Vol. 240(1), pp. 1-12.
	Suzuki et al., 1999, "Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives," <u>J. Med. Chem.</u> , Vol. 42, pp. 3001-3003.
	Takahashi, I., et al, 1996, "Selective inhibition of IL-2 gene expression by trichostatin A, a potent inhibitor of mammalian histone deacetylase," <u>J. Antibiot. (Tokyo)</u> , Vol. 49, No. 5, pp. 453-457.
	Taunton, J., et al., 1996, "A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p," <u>Science</u> , Vol. 272, pp. 408-411.
	Tsuji et al., 1976, "A New Antifungal Antibiotic, Trichostatin*," <u>J. Antibiot. (Tokyo)</u> , Vol. 29, No. 1, pp. 1-6.
	Ueda, H., et al., 1994, "FR901228, a novel antitumor bicyclic depsipeptide produced by <i>Chromobacterium violaceum</i> No. 968," <u>J. Antibiot. (Tokyo)</u> , Vol. 47(3), pp. 315-323.
	Van den Wyngaert et al., "Cloning and characterization of human histone deacetylase 8," 2000, <u>FEBS</u> , Vol. 478, pp. 77-83.
	Vigushin et al., 2001, "Trichostatin A Is a Histone Deacetylase Inhibitor with Potent Antitumor Activity against Breast Cancer <i>in vivo</i> ," <u>Clin. Cancer Res.</u> , Vol. 7, No. 4, pp. 971-976.
	Warrell et al., 1998, "Therapeutic Targeting of Transcription in Acute Promyelocytic Leukemia by Use of an Inhibitor of Histone Deacetylase," <u>J. Natl. Cancer Inst.</u> , Vol. 90, pp. 1621-1625.
	Wolfe, J.P., et al., 2000, "Scope and Limitations of the Pd/BINAP-Catalyzed Amination of Aryl Bromides," <u>J. Org. Chem.</u> , Vol. 65, pp. 1144-1157.
	Wolfe, J.P., et al., 2000, "Simple, Efficient Catalyst System for the Palladium-Catalyzed Amination of Aryl Chlorides, Bromides, and Triflates," <u>J. Org. Chem.</u> , Vol. 65, pp. 1158-1174.
	Wong, J., et al., 1998, "Distinct requirements for chromatin assembly in transcriptional repression by thyroid hormone receptor and histone deacetylase," <u>EMBO J.</u> , Vol. 17(2), pp. 520-534.
	Yang, W.M., et al., 1996, "Transcriptional repression of YY1 is mediated by interaction with a mammalian homolog of the yeast global regulator RPD3," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 93, pp. 12845-12850.

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

## INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.

**SERIAL NO.**

620-379

10/542,281

**APPLICANT**

FINN et al.

(Use several sheets if necessary)

FILING DATE

**GROUP**

July 15, 2005

unknown

**OTHER DOCUMENTS** (including Author, Title, Date, Pertinent pages, etc.)

[illegible]

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)